Alexion Pharma's Soliris drug obtains Japanese approval for treatment of aHUS

Alexion Pharmaceuticals has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the use of its drug 'Soliris' (eculizumab) to treat paediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), an ult…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news